223 related articles for article (PubMed ID: 26554929)
1. Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal Models.
Pytka K; Partyka A; Jastrzębska-Więsek M; Siwek A; Głuch-Lutwin M; Mordyl B; Kazek G; Rapacz A; Olczyk A; Gałuszka A; Błachuta M; Waszkielewicz A; Marona H; Sapa J; Filipek B; Wesołowska A
PLoS One; 2015; 10(11):e0142499. PubMed ID: 26554929
[TBL] [Abstract][Full Text] [Related]
2. HBK-7 - A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties.
Pytka K; Kazek G; Siwek A; Mordyl B; Głuch-Lutwin M; Rapacz A; Olczyk A; Gałuszka A; Waszkielewicz A; Marona H; Sapa J; Filipek B; Zygmunt M
Pharmacol Biochem Behav; 2016; 146-147():35-43. PubMed ID: 27132236
[TBL] [Abstract][Full Text] [Related]
3. Single Administration of HBK-15-a Triple 5-HT
Pytka K; Głuch-Lutwin M; Kotańska M; Waszkielewicz A; Kij A; Walczak M
Mol Neurobiol; 2018 May; 55(5):3931-3945. PubMed ID: 28550529
[TBL] [Abstract][Full Text] [Related]
4. HBK-14 and HBK-15, triple 5-HT
Pytka K; Socała K; Rapacz A; Nieoczym D; Pieróg M; Gryboś A; Siwek A; Waszkielewicz A; Wlaź P
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):378-385. PubMed ID: 28729118
[TBL] [Abstract][Full Text] [Related]
5. HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice.
Pytka K; Gawlik K; Pawlica-Gosiewska D; Witalis J; Waszkielewicz A
Metab Brain Dis; 2017 Apr; 32(2):547-556. PubMed ID: 27888375
[TBL] [Abstract][Full Text] [Related]
6. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A
Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
[TBL] [Abstract][Full Text] [Related]
7. The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1A) and 5-HT(2A/C) receptors activation.
Pytka K; Walczak M; Kij A; Rapacz A; Siwek A; Kazek G; Olczyk A; Gałuszka A; Waszkielewicz A; Marona H; Sapa J; Filipek B
Eur J Pharmacol; 2015 Oct; 764():537-546. PubMed ID: 26210317
[TBL] [Abstract][Full Text] [Related]
8. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
[TBL] [Abstract][Full Text] [Related]
9. HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels.
Pytka K; Głuch-Lutwin M; Kotańska M; Żmudzka E; Jakubczyk M; Waszkielewicz A; Janiszewska P; Walczak M
Behav Brain Res; 2017 Aug; 333():54-66. PubMed ID: 28648684
[TBL] [Abstract][Full Text] [Related]
10. New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation.
Chłoń-Rzepa G; Zmudzki P; Satała G; Duszyńska B; Partyka A; Wróbel D; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Pawłowski M; Zajdel P
Pharmacol Rep; 2013; 65(1):15-29. PubMed ID: 23563020
[TBL] [Abstract][Full Text] [Related]
11. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
Stachowicz K; Kłodzińska A; Palucha-Poniewiera A; Schann S; Neuville P; Pilc A
Neuropharmacology; 2009 Sep; 57(3):227-34. PubMed ID: 19539634
[TBL] [Abstract][Full Text] [Related]
12. HBK-17, a 5-HT
Pytka K; Głuch-Lutwin M; Żmudzka E; Sałaciak K; Siwek A; Niemczyk K; Walczak M; Smolik M; Olczyk A; Gałuszka A; Śmieja J; Filipek B; Sapa J; Kołaczkowski M; Pańczyk K; Waszkielewicz A; Marona H
Front Pharmacol; 2018; 9():1146. PubMed ID: 30410441
[TBL] [Abstract][Full Text] [Related]
13. The antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice.
Pytka K; Żmudzka E; Lustyk K; Rapacz A; Olczyk A; Gałuszka A; Waszkielewicz A; Marona H; Sapa J; Barbara F
Indian J Pharmacol; 2016; 48(3):286-91. PubMed ID: 27298499
[TBL] [Abstract][Full Text] [Related]
14. Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.
Jastrzębska-Więsek M; Siwek A; Partyka A; Antkiewicz-Michaluk L; Michaluk J; Romańska I; Kołaczkowski M; Wesołowska A
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):839-49. PubMed ID: 27106213
[TBL] [Abstract][Full Text] [Related]
15. Tert-butyl 4-((1-phenyl-1H-pyrazol-4-yl) methyl) piperazine-1-carboxylate (LQFM104)- New piperazine derivative with antianxiety and antidepressant-like effects: Putative role of serotonergic system.
da Silva DM; Sanz G; Vaz BG; de Carvalho FS; Lião LM; de Oliveira DR; Moreira LKDS; Cardoso CS; de Brito AF; da Silva DPB; da Rocha FF; Santana IGC; Galdino PM; Costa EA; Menegatti R
Biomed Pharmacother; 2018 Jul; 103():546-552. PubMed ID: 29677541
[TBL] [Abstract][Full Text] [Related]
16. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats.
Carr GV; Schechter LE; Lucki I
Psychopharmacology (Berl); 2011 Feb; 213(2-3):499-507. PubMed ID: 20217056
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.
Kassai F; Schlumberger C; Kedves R; Pietraszek M; Jatzke C; Lendvai B; Gyertyán I; Danysz W
Behav Pharmacol; 2012 Aug; 23(4):397-406. PubMed ID: 22785385
[TBL] [Abstract][Full Text] [Related]
19. Indorenate produces antidepressant-like actions in the rat forced swimming test via 5-HT1A receptors.
Martínez-Mota L; Estrada-Camarena E; López-Rubalcava C
Psychopharmacology (Berl); 2002 Dec; 165(1):60-6. PubMed ID: 12474119
[TBL] [Abstract][Full Text] [Related]
20. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
Kaminska K; Rogoz Z
J Physiol Pharmacol; 2016 Jun; 67(3):471-80. PubMed ID: 27512008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
